Fibrous Cap Thickness
Prior HUYGENS and PACMAN-AMI data showed PCSK9 inhibitors added to statins improved plaque morphology over 1 year, including increased fibrous cap thickness. The trial especially focuses on fibrous cap thickness as an OCT-measured plaque c…
1 sources - 5 claims
Prior HUYGENS and PACMAN-AMI data showed PCSK9 inhibitors added to statins improved plaque morphology over 1 year, including increased fibrous cap thickness. The trial especially focuses on fibrous cap thickness as an OCT-measured plaque characteristic during the first 6 months after ACS.